Online inquiry

IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13798MR)

This product GTTS-WQ13798MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13798MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ181MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ528MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 4D11
GTTS-WQ3733MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ8682MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ15178MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA T1h
GTTS-WQ728MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA A-623
GTTS-WQ766MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AB0024
GTTS-WQ10766MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-70
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW